Global histone modification patterns predict risk of prostate cancer recurrence (original) (raw)
- Letter
- Published: 30 June 2005
- Steve Horvath2,3 na1,
- Tao Shi2,3,
- Hong Yu1,
- Sheila Tze1,
- Michael Grunstein4 &
- …
- Siavash K. Kurdistani4
Nature volume 435, pages 1262–1266 (2005)Cite this article
- 8465 Accesses
- 830 Citations
- 11 Altmetric
- Metrics details
Abstract
Aberrations in post-translational modifications of histones have been shown to occur in cancer cells but only at individual promoters1; they have not been related to clinical outcome. Other than being targeted to promoters, modifications of histones, such as acetylation and methylation of lysine and arginine residues, also occur over large regions of chromatin including coding regions and non-promoter sequences, which are referred to as global histone modifications2. Here we show that changes in global levels of individual histone modifications are also associated with cancer and that these changes are predictive of clinical outcome. Through immunohistochemical staining of primary prostatectomy tissue samples, we determined the percentage of cells that stained for the histone acetylation and dimethylation of five residues in histones H3 and H4. Grouping of samples with similar patterns of modifications identified two disease subtypes with distinct risks of tumour recurrence in patients with low-grade prostate cancer. These histone modification patterns were predictors of outcome independently of tumour stage, preoperative prostate-specific antigen levels, and capsule invasion. Thus, widespread changes in specific histone modifications indicate previously undescribed molecular heterogeneity in prostate cancer and might underlie the broad range of clinical behaviour in cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
References
- Jacobson, S. & Pillus, L. Modifying chromatin and concepts of cancer. Curr. Opin. Genet. Dev. 9, 175–184 (1999)
Article CAS PubMed Google Scholar - Vogelauer, M., Wu, J., Suka, N. & Grunstein, M. Global histone acetylation and deacetylation in yeast. Nature 408, 495–498 (2000)
Article ADS CAS PubMed Google Scholar - Jemal, A. et al. Cancer statistics, 2003. CA Cancer J. Clinicians 53, 5–26 (2003)
Article Google Scholar - Gleason, D. F. Classification of prostatic carcinomas. Cancer Chemother. Rep. 50, 125–128 (1966)
CAS PubMed Google Scholar - Bunting, P. S. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin. Chim. Acta 315, 71–97 (2002)
Article CAS PubMed Google Scholar - Han, M., Partin, A. W., Piantadosi, S., Epstein, J. I. & Walsh, P. C. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J. Urol. 166, 416–419 (2001)
Article CAS PubMed Google Scholar - Farkas, A., Schneider, D., Perrotti, M., Cummings, K. B. & Ward, W. S. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 52, 444–448 (1998)
Article CAS PubMed Google Scholar - Giles, R. H., Peters, D. J. & Breuning, M. H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. 14, 178–183 (1998)
Article CAS PubMed Google Scholar - Gayther, S. A. et al. Mutations truncating the EP300 acetylase in human cancers. Nature Genet. 24, 300–303 (2000)
Article CAS PubMed Google Scholar - Muraoka, M. et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12, 1565–1569 (1996)
CAS PubMed Google Scholar - Debes, J. D. et al. p300 in prostate cancer proliferation and progression. Cancer Res. 63, 7638–7640 (2003)
CAS PubMed Google Scholar - Reid, J. L., Iyer, V. R., Brown, P. O. & Struhl, K. Coordinate regulation of yeast ribosomal protein genes is associated with targeted recruitment of Esa1 histone acetylase. Mol. Cell 6, 1297–1307 (2000)
Article CAS PubMed Google Scholar - Krebs, J. E., Fry, C. J., Samuels, M. L. & Peterson, C. L. Global role for chromatin remodeling enzymes in mitotic gene expression. Cell 102, 587–598 (2000)
Article CAS PubMed Google Scholar - Peterson, C. L. & Laniel, M. A. Histones and histone modifications. Curr. Biol. 14, R546–R551 (2004)
Article CAS PubMed Google Scholar - Suka, N., Suka, Y., Carmen, A. A., Wu, J. & Grunstein, M. Highly specific antibodies determine histone acetylation site usage in yeast heterochromatin and euchromatin. Mol. Cell 8, 473–479 (2001)
Article CAS PubMed Google Scholar - Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nature Med. 4, 844–847 (1998)
Article CAS PubMed Google Scholar - Kurdistani, S. K., Tavazoie, S. & Grunstein, M. Mapping global histone acetylation patterns to gene expression. Cell 117, 721–733 (2004)
Article CAS PubMed Google Scholar - Rezai-Zadeh, N. et al. Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev. 17, 1019–1029 (2003)
Article CAS PubMed PubMed Central Google Scholar - Breiman, L. Classification and Regression Trees (Wadsworth International, Belmont, California, 1984)
MATH Google Scholar - Breiman, L. Random forests. Mach. Learn. 45, 5–32 (2001)
Article Google Scholar - Shi, T., Seligson, D., Belldegrun, A. S., Palotie, A. & Horvath, S. Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod. Pathol. 18, 547–557 (2005)
Article CAS PubMed Google Scholar - Kaplan, E. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457–481 (1958)
Article MathSciNet Google Scholar - Cleveland, W. S. Visualizing Data (Hobart Press, Murray Hill, New Jersey, 1993)
Google Scholar - Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391–400 (2005)
Article CAS PubMed Google Scholar
Acknowledgements
We thank M. Vogelauer for suggestions on the manuscript, and V. Minin for help with the statistical analyses. T.S. was a doctoral trainee supported by the UCLA Integrative Graduate Education and Research Traineeship (IGERT) Bioinformatics Program funded by the NSF Division of Graduate Education (DGE). This work was funded partly by a National Cancer Institute (NCI)] grant through the Jonsson Comprehensive Cancer Center to D.B.S. and a Howard Hughes Medical Institute Fellowship and a UCLA Specialized Program Of Research Excellence (SPORE) in Prostate Cancer Career Development grant to S.K.K.
Author information
Author notes
- David B. Seligson and Steve Horvath: *These authors contributed equally to this work
Authors and Affiliations
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, California, 90095, Los Angeles, USA
David B. Seligson, Hong Yu & Sheila Tze - Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, 90095, USA
Steve Horvath & Tao Shi - Department of Biostatistics, School of Public Health, University of California, Los Angeles, California, 90095, USA
Steve Horvath & Tao Shi - Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, 90095, USA
Michael Grunstein & Siavash K. Kurdistani
Authors
- David B. Seligson
You can also search for this author inPubMed Google Scholar - Steve Horvath
You can also search for this author inPubMed Google Scholar - Tao Shi
You can also search for this author inPubMed Google Scholar - Hong Yu
You can also search for this author inPubMed Google Scholar - Sheila Tze
You can also search for this author inPubMed Google Scholar - Michael Grunstein
You can also search for this author inPubMed Google Scholar - Siavash K. Kurdistani
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toSiavash K. Kurdistani.
Ethics declarations
Competing interests
Reprints and permissions information is available at npg.nature.com/reprintsandpermissions. The authors declare no competing financial interests.
Supplementary information
Supplementary Table S1
Univariate Cox analysis of level of individual histone modifications and risk of tumour recurrence. (DOC 26 kb)
Supplementary Table S2
Relationship of histone modification groups with clinicopathologic parameters in low grade (Gleason score=2-6) prostate adenocarcinomas (_n_=104). (DOC 79 kb)
Supplementary Table S3
Relationship of histone modification groups with clinicopathologic parameters in low grade (Gleason score=5-6) prostate adenocarcinomas from the Michigan validation TMA (_n_=39). (DOC 80 kb)
Supplementary Figure S1
Histone modification antibodies are specific in immunohistochemistry. (PDF 916 kb)
Supplementary Figure S2
A ′simple rule′ involving H3 K4diMe and H3 K18Ac estimates the grouping of patients based on Random Forests clustering of all five histone modifications. (PDF 51 kb)
Supplementary Methods
Detailed protocols and procedures used in this study. (DOC 61 kb)
Rights and permissions
About this article
Cite this article
Seligson, D., Horvath, S., Shi, T. et al. Global histone modification patterns predict risk of prostate cancer recurrence.Nature 435, 1262–1266 (2005). https://doi.org/10.1038/nature03672
- Received: 21 February 2005
- Accepted: 25 April 2005
- Issue Date: 30 June 2005
- DOI: https://doi.org/10.1038/nature03672
This article is cited by
Editorial Summary
Histones in cancer
Reports of altered epigenetic histone modifications in cancer cells have focused on individual gene promoters and so far none of these changes has been related to clinical outcome. Now aberrations of ‘global’ histone modification have been observed in prostate tumour patients. These do relate to clinical outcome, and suggest a useful means of prognosis.